Highlights•Agents targeting resistant Gram-negative bacteria are in the antibacterial
pipeline.•Both broad and narrow spectrum agents are in clinical development.•Public …

Background: Infections caused by multi-drug resistant (MDR) Gram-negative bacteria
represent an ever-growing area of unmet medical need. To address this need, it is …

Introduction: In recent years, infections caused by multidrug-resistant bacterial pathogens
have become a huge issue to public healthcare systems. Indeed, the misuse of antibiotics …

Bacterial resistance to antimicrobial agents is a growing problem worldwide. Not only is
issue compounded by the fact that there are fewer pharmaceutical companies conducting …

The spread of multidrug-resistant bacteria is an ever-growing concern, particularly among
Gram-negative bacteria because of their intrinsic resistance and how quickly they acquire …

The spread of resistance among Gram-positive and Gram-negative bacteria represents a
growing challenge for the development of new antimicrobials. The pace of antibiotic drug …

Antibiotic-resistant Gram-negative bacteria are, arguably, the most difficult organisms to
treat, with a limited number of new antibiotics in the development pipeline. Currently 24 new …

New resistance challenges continue to evolve and spread worldwide. In an otherwise
mature field, antibacterial drug development is primarily driven by resistance trends with a …

New Antibiotics in Development Target Highly Resistant Gram-Negative Organisms - PMC
Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …

Introduction: Infections due to multidrug-resistant (MDR) bacteria are burdened by high
mortality rates. The development of new compounds to face the global threat of resistance is …